TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct...

Area of Science:

• Immunology
• Rheumatology
• Bone Biology

Background:

• Rheumatoid arthritis (RA) is characterized by bone loss driven by cytokines like RANKL and TNF-alpha.
• Osteoprotegerin (OPG) inhibits bone resorption, while anti-TNF-alpha antibodies target inflammation.
• The impact of anti-TNF-alpha antibodies on bone loss in RA models remains unclear.

Purpose of the Study:

• To investigate the effects of OPG and anti-TNF-alpha antibodies on inflammation and bone remodeling.
• To evaluate the efficacy of OPG and anti-TNF-alpha antibodies, alone and in combination, in a collagen-induced arthritis (CIA) mouse model.

Main Methods:

• DBA/1 mice were induced with collagen-induced arthritis (CIA).
• Mice were treated with OPG-Fc, anti-TNF-alpha antibodies, both, or saline.
• Bone mineral density (BMD), urinary deoxypyridinoline (D-pyr), and histomorphometric parameters were assessed.

Main Results:

• Anti-TNF-alpha antibodies reduced clinical and histological arthritis scores.
• Both OPG and anti-TNF-alpha antibodies increased BMD and reduced bone resorption markers (D-pyr).
• OPG increased bone volume and decreased bone formation rate, while anti-TNF-alpha antibodies preserved bone formation.

Conclusions:

• Systemic OPG and anti-TNF-alpha antibody therapies prevent bone loss in CIA mice via distinct mechanisms.
• OPG reduces bone resorption, and anti-TNF-alpha antibodies preserve bone formation.
• Combination therapy may be beneficial for preventing bone loss in inflammatory diseases.